Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to redu… Read more
Oragenics Inc (OGEN) - Total Assets
Latest total assets as of September 2025: $12.71 Million USD
Based on the latest financial reports, Oragenics Inc (OGEN) holds total assets worth $12.71 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oragenics Inc - Total Assets Trend (2003–2024)
This chart illustrates how Oragenics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oragenics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oragenics Inc's total assets of $12.71 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Oragenics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oragenics Inc's current assets represent 100.0% of total assets in 2024, an increase from 98.8% in 2003.
- Cash Position: Cash and equivalents constituted 58.7% of total assets in 2024, down from 98.2% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oragenics Inc Competitors by Total Assets
Key competitors of Oragenics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oragenics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oragenics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oragenics Inc is currently not profitable relative to its asset base.
Oragenics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.42 | 1.93 | 13.40 |
| Quick Ratio | 4.42 | 1.93 | 13.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.83 Million | $ 1.99 Million | $ 16.64 Million |
Oragenics Inc - Advanced Valuation Insights
This section examines the relationship between Oragenics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | -70.4% |
| Total Assets | $1.47 Million |
| Market Capitalization | $2.74 Million USD |
Valuation Analysis
Above Book Valuation: The market values Oragenics Inc's assets above their book value (1.86 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Oragenics Inc's assets decreased by 70.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oragenics Inc (2003–2024)
The table below shows the annual total assets of Oragenics Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.47 Million | -70.35% |
| 2023-12-31 | $4.97 Million | -66.35% |
| 2022-12-31 | $14.76 Million | -47.72% |
| 2021-12-31 | $28.23 Million | +51.13% |
| 2020-12-31 | $18.68 Million | -5.43% |
| 2019-12-31 | $19.75 Million | -10.42% |
| 2018-12-31 | $22.05 Million | +205.61% |
| 2017-12-31 | $7.21 Million | +67.43% |
| 2016-12-31 | $4.31 Million | -25.43% |
| 2015-12-31 | $5.78 Million | -48.09% |
| 2014-12-31 | $11.13 Million | -33.86% |
| 2013-12-31 | $16.83 Million | +60.48% |
| 2012-12-31 | $10.49 Million | +727.82% |
| 2011-12-31 | $1.27 Million | -26.67% |
| 2010-12-31 | $1.73 Million | -46.06% |
| 2009-12-31 | $3.20 Million | +100.92% |
| 2008-12-31 | $1.59 Million | +38.45% |
| 2007-12-31 | $1.15 Million | -28.30% |
| 2006-12-31 | $1.61 Million | -25.18% |
| 2005-12-31 | $2.15 Million | -51.94% |
| 2004-12-31 | $4.47 Million | +22.33% |
| 2003-12-31 | $3.65 Million | -- |